AX-2024-004452 · Hexarelin · GSP lot GSP-2311-C2917

Section 1

Results

Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	98.79	% area	≥ 99.0	FAIL
Total impurities	RP-HPLC, sum of reported peaks	1.21	% area	≤ 1.0	FAIL
Largest single impurity	RP-HPLC — oxidised Trp (+16 Da)	0.80	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	886.4602	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	886.4592	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-1.1	ppm	± 15	PASS
Total peptide content	by difference from the gravimetric mass balance	90.10	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	89.01	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	12.07	mg	10 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	10.744	mg	10 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	107.4	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	3.84	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	5.82	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.24	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Faint haze, clearing on standing	—	clear, no visible particulates	FAIL
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	6.16	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	8.79	min	8.92 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	0.86	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	66,488	—	≥ 20,000	PASS
Resolution to nearest impurity	vs C-terminal free acid (+1 Da)	1.14	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 66,488, and skew follows the reported asymmetry factor of 0.86. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.80 % impurity against a 98.79 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Hexarelin — main peak	8.79	4,801,500	98.79	—
2	oxidised Trp (+16 Da)	8.45	38,882	0.80	+15.995
3	des-methyl hexarelin (GHRP-6, −14 Da)	8.31	8,263	0.17	-14.016
4	des-Lys (−128 Da)	8.57	7,776	0.16	-128.095
5	C-terminal free acid (+1 Da)	8.95	3,888	0.08	+0.984
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 886.4602 Da, computed from C47H58N12O6. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 886.4592 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
2+	444.2374	444.2369	-0.0005	62.0
1+	887.4675	887.4665	-0.0010	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	3.84
Counter-ion (acetate)	ion chromatography	5.82
Residual solvent + inorganic residue	estimated	0.24
Total peptide content	by difference	90.10
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.45	98.79	divergence +0.44 pp vs batch median
Total impurities (% area)	0.55	1.21
Largest single impurity (% area)	0.25	0.80
Water (%)	3.6	3.84
Counter-ion (%)	not stated	5.82
Peptide content (%w/w)	91.6	90.10
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (ambient, 30 d) → laboratory (courier, cold pack, 9 d) → assay.
Assay date: 15 Feb 2024
Submitted to the index: 22 Feb 2024
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: VERIFIED

What this report does not establish

That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

mass_defect22 Feb 2024

Before assigning oxidised Trp (+16 Da) from retention alone, check the mass defect on the impurity peak. Plausible and implausible assignments separate cleanly and the check costs nothing.

hilic_hana22 Feb 2024

Purity 98.79 % with oxidised Trp (+16 Da) at 0.80 % nearby. Read the pair together: the purity figure and its nearest neighbour are two views of one integration decision.

hplc_ola22 Feb 2024

Flow rate is the free variable most operators never touch. Halving it on an isocratic hold across the pair is a fifteen-minute experiment with a definitive answer.

Section 7

Related records

Same batch — lot GSP-2311-C2917 n=3

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2024-004450	GSP-2311-C2917	Janoshik	2024-Q1	99.02	5.03	—	Buyer-sourced	0	PASS
AX-2024-004451	GSP-2311-C2917	Nordanalyt	2024-Q1	99.01	4.00	104.6	Buyer-sourced	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Hexarelin records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-042177	JEEP	JEEP-2608-Y9547	Janoshik	2026-Q3	99.90	3.42	—	Buyer-sourced	PASS
AX-2026-042178	JEEP	JEEP-2608-Y9547	VendorInvestigate	2026-Q3	99.68	4.03	—	Buyer-sourced	PASS
AX-2026-043097	KP	KP-2604-X5990	Medutest	2026-Q2	99.55	2.60	—	Laboratory-retained	PASS
AX-2026-043253	CPC	CPC-2511-F9455	Janoshik	2026-Q2	98.53	6.11	—	Buyer-sourced	FAIL
AX-2026-043098	KP	KP-2604-X5990	PeptideMeter	2026-Q2	98.66	3.14	—	Buyer-sourced	FAIL
AX-2026-042366	Homopeptide	HOMO-2602-R3080	Janoshik	2026-Q2	99.55	4.14	—	Buyer-sourced	PASS
AX-2026-042365	Homopeptide	HOMO-2602-R3080	PeptideMeter	2026-Q2	99.66	4.44	94.8	Buyer-sourced	PASS
AX-2026-043100	KP	KP-2604-X5990	Janoshik	2026-Q2	98.82	3.57	92.0	Buyer-sourced	FAIL

Other recent GSP records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041831	Survodutide	GSP-2603-E3156	Kestrel	2026-Q3	99.91	5.50	93.2	Buyer-sourced	0	PASS
AX-2026-041836	Survodutide	GSP-2603-E3156	Janoshik	2026-Q3	98.65	5.34	90.3	Buyer-sourced	0	PASS
AX-2026-041837	Survodutide	GSP-2603-E3156	Janoshik	2026-Q3	98.33	5.37	—	Buyer-sourced	0	PASS
AX-2026-041833	Survodutide	GSP-2603-E3156	Janoshik	2026-Q3	98.08	4.91	99.3	Buyer-sourced	0	PASS
AX-2026-041832	Survodutide	GSP-2603-E3156	VendorInvestigate	2026-Q3	98.01	5.14	99.5	Buyer-sourced	0	PASS
AX-2026-041835	Survodutide	GSP-2603-E3156	Nordanalyt	2026-Q3	98.34	5.74	89.0	Buyer-sourced	1	MARGINAL
AX-2026-041834	Survodutide	GSP-2603-E3156	VendorInvestigate	2026-Q3	97.92	5.95	—	Buyer-sourced	0	PASS
AX-2026-041838	Survodutide	GSP-2603-E3156	PeptideMeter	2026-Q3	98.30	5.01	102.4	Buyer-sourced	0	PASS